期刊文献+

Prevention of pelvic radiation disease 被引量:7

Prevention of pelvic radiation disease
下载PDF
导出
摘要 Pelvic cancers are among the most frequently diagnosed cancers worldwide. Treatment of patients requires a multidisciplinary approach that frequently includes radiotherapy. Gastrointestinal(GI) radiation-induced toxicity is a major complication and the transient or long-term problems, ranging from mild to very severe, arising in non-cancerous tissues resulting from radiation treatment to a tumor of pelvic origin, are actually called as pelvic radiation disease. The incidence of pelvic radiation disease changes according to the radiation technique, the length of follow up, the assessmentmethod, the type and stage of cancer and several other variables. Notably, even with the most recent radiation techniques, i.e., intensity-modulated radiotherapy, the incidence of radiation-induced GI side effects is overall reduced but still not negligible. In addition, radiation-induced GI side effects can develop even after several decades; therefore, the improvement of patient life expectancy will unavoidably increase the risk of developing radiation-induced complications. Once developed, the management of pelvic radiation disease may be challenging. Therefore, the prevention of radiation-induced toxicity represents a reasonable way to avoid a dramatic drop of the quality of life of these patients. In the current manuscript we provide an updated and practical review on the best available evidences in the field of the prevention of pelvic radiation disease. Pelvic cancers are among the most frequently diagnosed cancers worldwide. Treatment of patients requires a multidisciplinary approach that frequently includes radiotherapy. Gastrointestinal(GI) radiation-induced toxicity is a major complication and the transient or long-term problems, ranging from mild to very severe, arising in non-cancerous tissues resulting from radiation treatment to a tumor of pelvic origin, are actually called as pelvic radiation disease. The incidence of pelvic radiation disease changes according to the radiation technique, the length of follow up, the assessmentmethod, the type and stage of cancer and several other variables. Notably, even with the most recent radiation techniques, i.e., intensity-modulated radiotherapy, the incidence of radiation-induced GI side effects is overall reduced but still not negligible. In addition, radiation-induced GI side effects can develop even after several decades; therefore, the improvement of patient life expectancy will unavoidably increase the risk of developing radiation-induced complications. Once developed, the management of pelvic radiation disease may be challenging. Therefore, the prevention of radiation-induced toxicity represents a reasonable way to avoid a dramatic drop of the quality of life of these patients. In the current manuscript we provide an updated and practical review on the best available evidences in the field of the prevention of pelvic radiation disease.
出处 《World Journal of Gastrointestinal Pharmacology and Therapeutics》 CAS 2015年第1期1-9,共9页 世界胃肠药理与治疗学杂志(英文版)(电子版)
关键词 Pelvic radiation DISEASE Radiotherapy Gastrointestinal toxicity AMIFOSTINE AMINOSALICYLATES Sucralfate BECLOMETHASONE dipropionate Probiotics supplementation MISOPROSTOL MESALAZINE Pelvic radiation disease Radiotherapy Gastrointestinal toxicity Amifostine Aminosalicylates Sucralfate Beclomethasone dipropionate Probiotics supplementation Misoprostol Mesalazine
  • 相关文献

参考文献21

  • 1P Delia,G Sansotta,V Donato,P Frosina,G Messina,C De Renzis,G Famularo.Use of probiotics for prevention of radiation-induced diarrhea[J].World Journal of Gastroenterology,2007,13(6):912-915. 被引量:32
  • 2Santanu Pal,Shyam Adhikary,Biswamit Bhattacharya,Joydeep Basu,Tanmoy Ghosh,Niladri Patra.A prospective randomized controlled trial to study the role of sulfasalazine in prevention of acute gastrointestinal toxicity associated with concurrent chemoradiation in carcinoma cervix[J]. Clinical Cancer Investigation Journal . 2013 (2)
  • 3Rachel J. Gibson,Dorothy M. K. Keefe,Rajesh V. Lalla,Emma Bateman,Nicole Blijlevens,Margot Fijlstra,Emily E. King,Andrea M. Stringer,Walter J. F. M. Velden,Roger Yazbeck,Sharon Elad,Joanne M. Bowen.Systematic review of agents for the management of gastrointestinal mucositis in cancer patients[J]. Supportive Care in Cancer . 2013 (1)
  • 4Lorenzo Fuccio,Alessandra Guido,H. Jervoise N. Andreyev.Management of Intestinal Complications in Patients With Pelvic Radiation Disease[J]. Clinical Gastroenterology and Hepatology . 2012 (12)
  • 5J. Staffurth.A Review of the Clinical Evidence for Intensity-modulated Radiotherapy[J]. Clinical Oncology . 2010 (8)
  • 6H Jervoise N Andreyev,Andrew Wotherspoon,James W Denham,Martin Hauer-Jensen.Defining pelvic-radiation disease for the survivorship era[J]. Lancet Oncology . 2010 (4)
  • 7Linda J. Wedlake,Karen Thomas,Amyn Lalji,Peter Blake,Vincent S. Khoo,Diana Tait,H. Jervoise N. Andreyev.Predicting Late Effects of Pelvic Radiotherapy: Is There a Better Approach?[J]. International Journal of Radiation Oncology, Biology, Physics . 2010 (4)
  • 8Cynthia N. Rittenberg,Judith L. Johnson,Gerald M. Kuncio.An oral history of MASCC, its origin and development from MASCC’s beginnings to 2009[J]. Supportive Care in Cancer . 2010 (6)
  • 9Tereza Kertesz,Markus K. A. Herrmann,Antonia Zapf,Hans Christiansen,Robert M. Hermann,Olivier Pradier,Heinz Schmidberger,Clemens F. Hess,Andrea Hille.Effect of a Prostaglandin – Given Rectally for Prevention of Radiation-Induced Acute Proctitis – on Late Rectal Toxicity[J]. Strahlentherapie und Onkologie . 2009 (9)
  • 10Anurag K. Singh,Cynthia Ménard,Peter Guion,Nicole L. Simone,Sharon Smith,Nancy Sears Crouse,Denise J. Godette,Theresa Cooley-Zgela,Linda C. Sciuto,Jonathan Coleman,Peter Pinto,Paul S. Albert,Kevin Camphausen,C. Norman Coleman.Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: A pilot study[J]. International Journal of Radiation Oncology, Biology, Physics . 2006 (4)

二级参考文献19

  • 1[1]Donner CS.Pathophysiology and therapy of chronic radiation-induced injury to the colon.Dig Dis 1998; 16:253-261
  • 2[2]Vails A,Pestchen I,Prats C,Pera J,Aragon G,Vidarte M,Algara M.Multicenter double-blind clinical trial comparing sucralf ate vs placebo in the prevention of diarrhea secondary to pelvic irradiation.Med Clin (Bare) 1999; 113:681-684
  • 3[3]Kneebone A,Mameghan H,Bolin T,Berry M,Turner S,Kearsley J,Graham P,Fisher R,Delaney G.Effect of oral sucralfate on late rectal injury associated with radiotherapy for prostate cancer:A double-blind,randomized trial,lnt J Radiat Oncol Biol Phys 2004; 60:1088-1097
  • 4[4]Dodd MJ,Miaskowski C,Greenspan D,MacPhail L,Shih AS,Shiba G,Fadone N,Paul SM.Radiation-induced mucositis:a randomized clinical trial of micronized sucralfate versus salt & soda mouthwashes.Cancer Invest 2003; 21:21-33
  • 5[5]Resbeut M,Marteau P,Cowen D,Richaud P,Bourdin S,Dubois JB,Mere P,N'Guyen TD.A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis.Radiother Oncol 1997; 44:59-63
  • 6[6]Jahraus CD,Bettenhausen D,Malik U,Sellitti M,St Clair WH.Prevention of acute radiation-induced proctosigmoiditis by balsalazide:a randomized,double-blind,placebo controlled trial in prostate cancer patients.Lnt J Radiat Oncol Biol Phys 2005; 63:1483-1487
  • 7[7]Kozelsky TF,Meyers GE,Sloan JA,Shanahan TG,Dick SJ,Moore RL,Engeler GP,Frank AR,McKone TK,Urias RE,Pilepich MV,Novotny PJ,Martenson JA.Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy.J clin Oncol 2003; 21:1669-1674
  • 8[8]Yavuz MN,Yavuz AA,Aydin F,Can G,Kavgaci H.The efficacy of octreotide in the therapy of acute radiation-induced diarrhea:a randomized controlled study,lnt J Radiat Oncol Biol Phys 2002; 54:195-202
  • 9[9]Martin T,Uhder K,Kurek R,Roeddiger S,Schneider L,Vogt HG,Heyd R,Zamboglou N.Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial.Radiother Oncol 2002; 65:17-22
  • 10[10]Kneebone A,Mameghan H,Bolin T,Berry M,Turner S,Kearsley J,Graham P,Fisher R,Delaney G.The effect of oral sucralfate on the acute proctitis associated with prostate radiotherapy:a double-blind,randomized trial.Int J Radiat Oncol Biol Phys 2001; 51:628-635

共引文献34

同被引文献39

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部